TNBC - TRIPLE-NEGATIVE BREAST CANCER

This study tests whether an MRI scan can identify triple-negative breast cancer patients who respond well to initial treatment, allowing them to skip a second, more toxic chemotherapy phase. About 54 participants will receive a standard first phase of chemo plus immunotherapy, th…

This study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left in t…

This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors or slow their growth. About 430 adults with certain breast, ovarian, or endometrial c…

This study tests a new approach for people with triple-negative breast cancer whose tumors did not shrink after initial chemotherapy. Participants receive a short course of high-precision radiation to the breast tumor, followed by immunotherapy (toripalimab) combined with more ch…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is a hard-to-treat type of breast cancer with fewer treatment options. The trial will e…

This program provides early access to an investigational drug called leronlimab for people with advanced triple-negative breast cancer who have run out of standard treatments. Participants must have stage IIIB or IV cancer that has worsened after prior therapy. The goal is to off…

This early-phase study tests a new treatment called 177Lu-RAD204, which combines a radioactive particle with an antibody that targets a protein (PD-L1) found on many cancer cells. The goal is to see if it is safe and how it spreads in the body. About 30 adults with advanced lung,…

This trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are monitored closely…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and works better than radiation alone for people with metastatic breast cancer. About 34 adults with triple-negative or hormone-…

This study tests a new mix of drugs (alpelisib, L-NMMA, and chemo) for people with a rare, aggressive breast cancer called metaplastic breast cancer that has spread or cannot be removed. The goal is to see if the combination is safe and shrinks tumors. About 36 adults who have no…

This phase 2 trial tests whether injecting the drug INT230-6 into the tumor before standard chemotherapy and immunotherapy can increase the chance of eliminating all cancer in the breast and lymph nodes before surgery. About 61 people with early triple-negative breast cancer will…

This study tests whether adding a drug called axatilimab (which targets immune cells) and radiation to standard immunotherapy (pembrolizumab) can completely eliminate triple-negative breast cancer before surgery. About 35 women with high-risk, early-stage disease will receive thi…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, ovarian, or lung cancer) that haven't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors, either alone or combine…

This early-phase study tests a new immunotherapy drug (QL1706) combined with a short course of chemotherapy for people with early-stage triple-negative breast cancer (TNBC), a fast-growing and hard-to-treat type. The goal is to see if this combination can eliminate the tumor befo…

This study is testing whether adding an immunotherapy drug called toripalimab to standard chemotherapy before surgery can help eliminate triple-negative breast cancer tumors. It will involve about 35 women with early-stage disease to see if this combination leads to no detectable…

This is a first-in-human study to test the safety and find the right dose of a new drug called BAL0891. It will be given alone and in combination with other cancer drugs to 260 adults with advanced solid tumors (like certain breast and stomach cancers) or a type of leukemia that …

This study is testing a new experimental drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to find and deliver radiation directly to cancer cells. The main goals are to f…

This study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether chemotherapy has eliminated all cancer before surgery. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms d…

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. The goal is to see if the device can accurately predict when the cancer is completely gone. About 15 women with specific breast cancer types will be enrolle…

This study looks at how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. It involves 300 Chinese adults whose cancer has worsened after first treatment. The goal is to see which option better maintai…

This study looks at whether changes in a simple blood marker called CRP can help predict how well immunotherapy works in people with triple-negative breast cancer. Researchers will follow 225 women with early or advanced cancer who are receiving immunotherapy. The goal is to see …

This study tests whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It enrolls 5,000 participants with early-stage or locally advanced breast cancer. The goal is to learn which drug works best for whic…

This study collects live tumor samples from 2,000 people with various cancers to understand why some respond to immunotherapy and others don't. Participants undergo a standard biopsy as part of their care, and the tissue is analyzed in the lab. The goal is to develop better ways …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding these leftover cells, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 breast cancer p…